Stocks of Esperion Therapeutics Inc. (NASDAQ:ESPR) traded higher last session on Wall Street, down -2.07% to $1.89.
ESPR stock price is now 3.43% away from the 50-day moving average and -16.48% away from the 200-day moving average. The market capitalization of the company currently stands at $370.86M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $2.50, BofA Securities recently Downgraded its rating from Neutral to Underperform for Esperion Therapeutics Inc. (NASDAQ: ESPR). , while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, Koenig Sheldon L., President and CEO sold 14,550 shares of the company’s stock on Sep 17 ’24. The stock was sold for $26,132 at an average price of $1.80. Upon completion of the transaction, the President and CEO now directly owns 752,266 shares in the company, valued at $1.42 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 17 ’24, Chief Commercial Officer Warren Eric sold 2,608 shares of the business’s stock. A total of $4,650 was realized by selling the stock at an average price of $1.78. This leaves the insider owning 162,659 shares of the company worth $0.31 million. A total of 1.05% of the company’s stock is owned by insiders.
During the past 12 months, Esperion Therapeutics Inc. has had a low of $0.70 and a high of $3.40. The fifty day moving average price for ESPR is $1.8274 and a two-hundred day moving average price translates $2.2631 for the stock.
The latest earnings results from Esperion Therapeutics Inc. (NASDAQ: ESPR) was released for 2024-06-30. The company reported revenue of $73.83 million for the quarter, compared to $25.79 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 186.33 percent.
